Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy

Cerebrospinal fluid amyloid biomarkers distinguished sporadic and hereditary cerebral amyloid angiopathy from healthy controls and patients with Alzheimer disease.

Cerebral amyloid angiopathy (CAA) clinically presents with intracerebral hemorrhage (ICH), cognitive impairment, or transient focal neurological symptoms and is diagnosed by lobar hemorrhage, microbleeds, and superficial siderosis on MRI brain imaging or, ideally, a brain biopsy. Cerebrospinal fluid (CSF) biomarkers may assist in earlier diagnosis. In this study, researchers compared CSF amyloid beta (Aβ) 38, Aβ40, Aβ42, and Aβ43 levels in patients diagnosed with spontaneous CAA (n=66), hereditary CAA (n=22), Alzheimer disease (AD; n=40), and nondemented controls (n=77).

All CSF Aβ isoform levels were lower in patients with spontaneous or hereditary CAA than in controls after adjustment for age and sex, with differences more pronounced for A…

Reviewing Author

Jennifer Rose V. Molano, MD

Disclosures

Grant/Research SupportNational Center for Advancing Translational Science – Cincinnati Center for Clinical and Translational Science and Training

Editorial BoardsBrain & Life

Jennifer Rose V. Molano, MD

Disclosures

Grant/Research SupportNational Center for Advancing Translational Science – Cincinnati Center for Clinical and Translational Science and Training

Editorial BoardsBrain & Life

Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy

Topics

Reviewing Author